Hüppa põhisisu juurde
Raamatukoi
Tõde ja õigus

Drug Discovery for Leishmaniasis

Luis Spain) Rivas, Carmen Spain) Gil (toim.) · Royal Society of Chemistry · 2017

Drug Discovery for Leishmaniasis

For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the Leishmania enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where Leishmania resides.

Drug Discovery for Leishmaniasis aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.

Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.

Saadavus
238,00 €

Uus kasutamata raamat

Täna tellides on tarneaeg umbes 10 päeva (27.11.2026)Tellimuse täitmise aeg on umbkaudne ja sõltub nädalapäevast, millal tellimus tehakse. Reeglina ei kulu üle kahe nädala.

Tarne ja kättesaamine

Detailid

Autorid
Luis Spain) Rivas, Carmen Spain) Gil (toim.)
ISBN
9781782628897
Aasta
2017
Keel
inglise
Köide
Kõva kaas
Lehekülgi
402
Teema
Meditsiin › Meditsiini muud erialad — Other branches of medicine
Kaal
788 g